October 28, 2013

Bing Wang Discusses Chinese Investigations on Drug Firms with South China Morning Post

Chinese drug companies' product sales have taken a hit due to investigations of corruption by the Chinese government on drug multinationals operating in the country. The chief executive at GlaxoSmithKline (GSK) believes that media coverage in China has created anxiety amongst the populace that have led to a decline in business, with sales for GlaxoSmithKline specifically dropping by more than 60 percent in the third quarter of 2013.

Bing Wang, partner in Faegre Baker Daniels' Beijing office, told the South China Morning Post that in light of the investigations, "foreign drug companies must adjust their model."

The Faegre Baker Daniels website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Baker Daniels' cookies information for more details.